Please assess the completion status of the following clinical trial:

Trial Title: Data Registry Following Patients Using Supera Stent in the Femoral Arteries

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Exclusion Criteria:~(Clinical)~* Patient or legal guardian understands registry procedures and has voluntarily signed an informed consent in accordance with institutional and local regulatory policies. (Note: Retrospective data may be collected and entered into the EDC system after a fully executed informed consent has been provided).~* Rutherford-Becker classification 2 through 5 only~* Patient is at least 18 years of age and of legal age of consent.~* Patient must be willing to participate in the registry for at least 5 years.~(Angiographic)~* Target lesion is a single de novo or restenotic (outside a stent) SFA or Popliteal artery lesion ≥ 1 cm from origin of another stent; additional lesions may be present., but there is only one target lesion~* All SFA target lesions are to be located with the proximal point at least 2 cm below the origin of the profunda femoris artery.~* All Popliteal Artery target lesions are to be located with the most distal point at least 1 cm proximal to the bifurcation of the anterior tibial artery and the tibioperoneal trunk.~* Target lesion length 1-20 cm (visual estimate)~* Target lesion stenosis ≥50% (visual estimate)~* Popliteal artery patent if the lesion is in the SFA~* SFA patent if the lesion is in the popliteal artery~* At least one widely patent (\< 50% stenosis) infrapopliteal artery (for distal run-off)~Exclusion Criteria:~(Clinical)~* Evidence of heparin induced thrombocytopenia (HIT), or intravenous tPA, Plavix, Ticlid, or aspirin therapy sensitivities~* Patient is participating in a clinical study that could confound results~* Patient is pregnant/breastfeeding at time enrollment or plans to become pregnant during the course of participation in the registry.~(Angiographic)~* Target lesion length \> 20 cm~* Instent restenotic / reoccluded target lesion~* Acute (≤ 4 weeks) thrombotic occlusion~* Untreated ipsilateral pelvic stenosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Device SUPERA Stent (Type: OTHER): SUPERA Interwoven Self-Expanding Nitinol Stent System

Based on this trial design, predict the completion outcome and termination type (if applicable).